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Dialysis therapy for end-stage renal disease (ESRD) continues to be the readily available
renal replacement option in developing countries. While the impact of rural/remote dwelling
on mortality among dialysis patients in developed countries is known, it remains to be
defined in sub-Saharan Africa.
Methods
A single-center database of end-stage renal disease patients on chronic dialysis therapies
treated between 2007 and 2014 at the Polokwane Kidney and Dialysis Centre (PKDC) of
the Pietersburg Provincial Hospital, Limpopo South Africa, was retrospectively reviewed.
All-cause, cardiovascular, and infection-related mortalities were assessed and associated
baseline predictors determined.
Results
Of the 340 patients reviewed, 52.1% were male, 92.9% were black Africans, 1.8% were
positive for the human immunodeficiency virus (HIV), and 87.5% were rural dwellers. The
average distance travelled to the dialysis centre was 112.3 ± 73.4 Km while 67.6% of
patients lived in formal housing. Estimated glomerular filtration rate (eGFR) at dialysis initia-
tion was 7.1 ± 3.7 mls/min while hemodialysis (HD) was the predominant modality offered
(57.1%). Ninety-two (92) deaths were recorded over the duration of follow-up with the major-
ity (34.8%) of deaths arising from infection-related causes. Continuous ambulatory
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peritoneal dialysis (CAPD) was a significant predictor of all-cause mortality (HR: 1.62, CI:
1.07–2.46) and infection-related mortality (HR: 2.27, CI: 1.13–4.60). On multivariable cox
regression, CAPD remained a significant predictor of all-cause mortality (HR: 2.00, CI:
1.29–3.10) while the risk of death among CAPD patients was also significantly modified by
diabetes mellitus (DM) status (HR: 4.99, CI: 2.13–11.71).
Conclusion
CAPD among predominantly rural dwelling patients in the Limpopo province of South Africa
is associated with an increased risk of death from all-causes and infection-related causes.
Introduction
Renal transplantation remains the most cost-effective treatment option in end-stage renal dis-
ease (ESRD), providing a better quality of life and extending survival. It however still remains a
poorly utilized option in developing countries due to issues of poor infrastructure, technical
manpower shortages, and cultural and religious beliefs about organ donation.[1, 2] Chronic
dialysis therapies (hemodialysis and peritoneal dialysis) therefore remain the more readily
available treatment options for ESRD patients in developing countries. Among countries in
sub-Saharan Africa (SSA) in which maintenance dialysis is available, haemodialysis (HD),
rather than peritoneal dialysis (PD), is often the modality of choice, mainly due to the high cost
of performing and maintaining continuous ambulatory peritoneal dialysis (CAPD) pro-
grammes, unavailability of peritoneal dialysis fluids in some countries, an increased risk of
peritonitis given the generally high burden of infectious diseases, and lower physician reim-
bursement for CAPD.[3–5]
Dialysis patients have a higher mortality risk than matched individuals in the general popu-
lation with the identified factors for the increased risk including race, dialysis modality and the
inordinate occurrence of both traditional (hypertension, diabetes, dyslipidemia) and non-tradi-
tional (anemia, fluid overload, calcium-phosphate imbalance) cardiovascular (CV) risk factors
among these patients.[6, 7] Higher mortality rates have been observed among Caucasian
patients while PD appears to confer a survival advantage relative to HD, especially among non-
diabetics—an advantage which declines with increasing dialysis vintage.[8, 9] Survival out-
comes among maintenance dialysis patients in developing countries have shown a greater
annual cumulative survival among HD patients in comparison to CAPD patients (73.4% versus
62%).[10] Data from South Africa however shows similar cumulative survival (approximately
88%) for both modalities.[10] Infection in addition to CV factors are the leading identified
causes of death.
Access to renal replacement modalities is a challenge in developing countries due to scarce
resources and competing economic choices which limit the number of dialysis centers within
communities/regions. In addition to determining the associations between patient-related and
modality-related factors and mortality, focus has also centered on the relationship between
proximity to health care services and hard patient outcomes such as mortality in CKD and
ESRD. Thompson et al demonstrated that chronic dialysis patients living greater than 100
miles from dialysis centres in the United States of America had a 21.0% increased risk of mor-
tality; no association was however shown between dwelling (rural or urban) and dialysis-
related mortality.[11]
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The determinants of mortality among rural dwelling South Africans on maintenance dialy-
sis therapies is unknown and we thus sought to identify the prevailing causes and predictors of




This study is a retrospective analysis of a single-center ESRD database of patients treated with
HD or CAPD at the Polokwane Kidney and Dialysis Centre (PKDC) of the Pietersburg Provin-
cial Hospital, Limpopo South Africa. The study received approval from the Pietersburg Provin-
cial Hospital Ethics Committee.
The period under review was from 2007 (when PKDC was commissioned) to July 2014. All
incident dialysis patients treated at the unit during the period under review were included.
Patients were included if they had been on stable dialysis for at least 3 months. Twenty (20)
patients who had started dialysis before 2007 at other centres and who continued dialysis with
the unit due to proximity considerations were also included in our review. The outcomes of
340 patients were thus determined. Dialysis modality at day 91 after dialysis initiation (60 days
of which the patient would have continuously been on the modality) was taken as the predomi-
nant modality. Duration of follow up for each modality was calculated from the date of starting
dialysis to date of last date of follow up (31st July 2014), or date of transplantation, or date of
death.
Covariates
We collected relevant socio-demographic data such as age at initiation of dialysis, gender, mar-
ital status, race, socio-economic status, predominant area of dwelling (urban versus rural), and
housing characteristics (formal or informal). Baseline (at dialysis initiation) clinical and bio-
chemical parameters collected included weight, body mass index (BMI), systolic and diastolic
blood pressures, estimated glomerular filtration rate (eGFR), serum albumin, serum choles-
terol, serum ferritin, transferrin saturation, calcium, inorganic phosphate, and parathyroid hor-
mone. The cause of ESRD was also ascertained. The cause was reported as unknown in those
patients who were late presenters; however if the cause despite late presentation was apparent
(e.g. polycystic kidney disease) a definite cause was allotted.
Outcomes and Definitions
Death within each modality was the outcome of interest of this study. Causes of death were
divided into CV, infection-related or other causes. We defined CV death as death resulting
from stroke, heart failure, myocardial infarction, pulmonary embolism or any death reported
to have occurred suddenly with no other known cause. Infection-related deaths were deaths
related to any ongoing infection at the time of death and these included peritonitis (for patients
on PD), pneumonia, tuberculosis, catheter-related blood stream infection(CRBSI), infective
endocarditis (one case) and empyema thoracis (one case). Deaths recorded as others were
deaths at home that were not medically certified, and malignancy-related deaths.
Statistical analysis
Patients’ data were anonymized and de-identified prior to statistical analysis. The data was ana-
lyzed using the Stata1 13 software (Stata Corp, Texas). Continuous variables are presented as
means and standard deviation (SD), and median with interquartile ranges where applicable.
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Categorical variables were presented as frequencies and percentages. Univariate analysis was
performed using the independent student’s t-test, or Wilcoxon rank sum test where appropri-
ate. Chi-squared test was used to compare categorical variables as appropriate. Kaplan-Meier
survival analysis was used to determine the median time-to-survival of patients with the log
rank test applied to explore significant difference in survival between dialysis modalities. Cen-
soring occurred at loss-to-follow up, elective withdrawal from the dialysis program or kidney
transplantation, whichever occurred first. Univariate Cox proportional regression analysis was
performed to determine the association between baseline characteristics and all-cause and
cause-specific mortalities (CV and infection-related mortalities). Variables with p<0.25 on
univariate cox regression analysis were entered into the multivariable Cox regression to deter-
mine the baseline predictor(s) of all-cause mortality. Survival analysis was based on an inten-
tion-to-treat analysis hence modality switches during the study period were not taken into
account. In assessing cause-specific mortalities, a cumulative incidence competing-risk analysis
was utilized.[12] Missing data points on assessed covariates were adjudged to be missing at ran-
dom and were subsequently multiply imputed. A p-value< 0.05 was considered statistical
significant.
Results
Table 1 summarises the baseline features of all the patients in this study. The average age was
36.1±11.9 years, with a slight preponderance of male patients (52.1%). The majority of patients
Table 1. Baseline demographic and clinical characteristics of patients according to modality.
Baseline Characteristic All Patients (n = 340) HD patients (n = 194) CAPD patient (n = 146) p-value
Age at start of dialysis (Years) 36.1 ± 11.9 43.3 ± 12.0 35.3 ± 11.5 0.35
Gender (Male / Female) (%) 52.1/47.9 47.4/52.6 51.4/48.6 0.83
Race: (%)
- Blacks 92.9 93.8 91.8 0.32
- Whites 5.0 4.6 5.5
- Others** 2.1 1.6 2.7
Predominant area of dwelling [rural locale] (%) 87.5 85.2 90.7 0.13
Type of housing [Formal] % 67.6 67.6 80.7 0.01*
Distance to Dialysis unit (km) 112.3 ± 73.4 110.7 ± 75.9 114.3 ± 70.2 0.66
BMI (kg/m2) 23.9 ± 5.5 23.6 ± 5.0 24.3 ± 6.3 0.37
eGFR [MDRD] (mls/min) 7.1 ± 3.7 7.0 ± 0.1 7.3 ± 0.1 0.11
SBP (mmHg) 140.1 ± 27.1 141.5 ± 26.3 137.9 ± 28.1 0.25
DBP (mmHg) 84.6 ± 17.7 84.4 ± 16.8 84.8 ± 19.0 0.87
Cause of ESRD: (%) 0.12
- Diabetes 10.3 11.3 8.9
- Hypertension 25.9 22.7 30.1
- Glomerulonephritis 6.8 8.3 4.8
- Unknown 45.0 45.4 44.5
- Others*** 12.0 12.3 11.7
Duration of follow up 36.6 ± 25.4 43.3 ± 26.3 27 ± 21.4 <0.001*#
* P < 0.05
**Others—Mixed ancestry, Indians and Asians
***Others—Unknown causes, Autosomal dominant polycystic kidney disease, Obstructive uropathy, chronic interstitial Nephritis
# Wilcoxon rank sum test
doi:10.1371/journal.pone.0156642.t001
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(92.9%) were of black African ancestry while, in keeping with the geo-demography of Lim-
popo, many of the patients (87.5%) were rural dwellers. The average distance travelled from
patients’ homes to the dialysis centre was 112.3 ± 73.4km. Approximately 60.0% of the patients
were treated with HD (Table 1). As a result of late presentation, the cause of ESRD remained
unknown in 45.0% while hypertension, diabetes mellitus and glomerulonephritis accounted for
25.9%, 10.3% and 6.8% respectively of all dialyzed patients. There was no difference in eGFR at
dialysis initiation between HD and CAPD patients. Six (3.1%) of the patients on HD were posi-
tive for the human immunodeficiency virus (HIV) while there were no HIV positive patients
on CAPD. Only 4 patients (1.1%) received kidney transplants (living donors) during the period
of follow up. Other clinical characteristics of the patients are shown in Table 1.
Differences between HD and CAPD patients with respect to baseline socio-demographic
and clinical parameters are also shown in Table 1. There was no difference in age, gender, race,
or predominant area of dwelling between both groups. There was a statistically significant dif-
ference however in the type of housing, with more CAPD patients dwelling in formal houses
(HD vs PD: 67.6% vs 80.7%, p = 0.01). Although the distance travelled to get to the dialysis
unit was longer in the CAPD patients, this was not significantly different from the distance
travelled by HD patients. The duration of follow-up was statistically shorter among PD patients
(HD vs PD, 43.3 ± 26.3 months vs. 27.0 ± 21.4 months, p< 0.001)
Table 2 depicts the differences between HD and CAPD patients with regards to baseline bio-
chemical parameters. HD patients were more likely to have lower serum albumin (28.2 ±6.7 vs
28.6 ± 6.6, p = 0.04) and serum cholesterol levels (4.1 ± 1.3 vs 4.5 ± 1.3, p = 0.001) at dialysis
initiation. CAPD patients had higher haemoglobin levels than HD patients (9.1±2.3 vs
8.4 ± 2.1, p = 0.001) and were also on lesser doses of subcutaneous erythropoietin than HD
patients [10,000 (8,000–12,000) units/week vs 12,000 (8,000–12,000) units/week, p = 0.001].
A total of 92 deaths (27.1%) occurred over the duration of follow up. Although there were
more deaths among HD patients, this was not statistically different from deaths among CAPD
patients (55.4% vs 44.6% p = 0.812). There were a total of 27 CV deaths (29.3%) and 32 infec-
tion-related deaths (34.8%). A higher proportion of CV deaths was recorded among females
(55.6% vs 44.4%) while a greater proportion of infection-related deaths occurred in males
(53.1% vs 43.8%) [not shown in Tables].
Fig 1 depicts all-cause mortality survival curves of HD and CAPD patients. There was a sig-
nificant difference in survival times between HD and CAPD patients (log rank test< 0.001).
Approximately a third (30%) of HD and CAPD patients had died at 49.4 (CI: 47.6–63.5)
Table 2. Baseline biochemical parameters of patients according to dialysis modality.
Biochemical Parameter All patients N = 340 HD patients (n = 194) CAPD patients (n = 146) p-value
Serum albumin (g/L) 28.4 ± 6.7 28.2 ±6.7 28.6 ± 6.6 0.04*
Total Cholesterol (mmol/L) 4.3 ± 1.4 4.1 ± 1.3 4.5 ± 1.3 0.001*
Serum corrected calcium (mmol/L) 2.4 ± 0.3 2.4 ± 0.3 2.4 ± 0.3 0.68
Serum phosphate (mmol/L) 1.4 (1.0–2.1) 1.4 (1.04–2.1) 1.5 (1.0–2.1) 0.16
CXP (mmol2/L2) 3.9 ± 2.3 4.0 ± 2.6 3.7 ± 1.8 0.002
Serum haemoglobin (g/dl) 8.7 ± 2.2 8.4 ± 2.1 9.1 ± 2.3 0.001*
Serum Ferritin 414.0 (204.0–714.5) 425.0 (196.0–755.0) 410.0 (206.0–677.0) 0.60
Transferrin saturation (%) 26.0 (15.0–44.0) 26.0 (15.0–48.1) 27.0 (16.0–41.0) 0.21
EPO (units/week) 10,000 (8,000–12,000) 10,000 (8,000–12,000) 12,000 (8,000–12,000) 0.001*
* p<0.05
doi:10.1371/journal.pone.0156642.t002
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Fig 1. Kaplan-Meier survival curve for all-causemortality according to dialysis modality.
doi:10.1371/journal.pone.0156642.g001
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months and 34.1 (CI: 30.6–36.6) months respectively. Fig 2a and 2b show the cause-specific
survival curves of infection-related mortality and CV mortality respectively.
Table 3 shows the relative risks (hazard ratios) of death due to all causes and specific causes
on univariate cox regression analysis. Patients on CAPD had a 62% increased risk of death
from all causes as well as a greater than 2-fold increase in the risk of death from infectious
causes. Significantly as well, there was a 10% reduction in the risk of death (all-cause mortality)
for every unit increase in haemoglobin levels. Although it was not of statistical significance,
patients with DM had almost twice the risk of death from CV causes in comparison to non-dia-
betics. Weight at initiation of dialysis was however significantly associated with the risk of CV
death (HR: 0.97, CI: 0.95–0.99, p = 0.04).
In assessing potential baseline predictors of all-cause mortality, CAPD remained an inde-
pendent predictor of all-cause mortality (HR: 2.00, CI: 1.29–3.10) after adjusting for weight at
Fig 2. Kaplan-Meier survival curves cause-specific mortality according to dialysis modality. a. Infection-
related mortality. b. Cardiovascular mortality.
doi:10.1371/journal.pone.0156642.g002
Table 3. Univariate Hazard ratios for all-cause and cause-specific mortality.
Characteristic All-cause Mortality CV mortality Infection-related mortality
Modality (PD) 1.62 (1.07–2.46)* 1.34 (0.62–2.88) 2.27 (1.13–4.60)*
Age (years) 1.00 (0.98–1.-02) 1.02 (0.99–1.06) 1.00 (0.97–1.03)
Gender (male) 0.89 (0.59–1.34) 0.83 (0.39–1.78) 1.24 (0.61–2.51)
Distance to centre (50 Km) 1.00 (0.99–1.00) 1.00 (0.99–1.01) 1.09 (0.88–1.35)
Housing (Informal) 1.28 (0.82–2.03) 1.30(0.54–3.25) 1.32 (0.61–2.85)
Diabetes mellitus (present) 1.43 (0.79–2.56) 1.86(0.73–4.80) 1.62 (0.62–4.23)
Hypertension (present) 0.88 (0.54–1.43) 0.84 (0.34–2.09) 1.24 (0.52–2.67)
Weight (kg) 0.99 (0.98–1.00) 0.97 (0.95–0.99)* 1.01 (0.99–1.02)
sAlbumin (g/L) 0.98 (0.99–1.01) 0.99 (0.94–1.06) 0.98 (0.93–1.04)
sCholesterol (mmol/L) 1.03 (0.86–1.23) 0.93 (0.66–1.30) 1.08 (0.68–1.72)
Corrected Calcium (mmol/L) 1.25 (0.61–2.57) 2.46 (0.49–12.23) 0.95 (0.25–3.63)
CXP (mmol2/L2) 0.86 (0.75–0.99)* 0.71 (0.55–0.90)* 0.84 (0.68–1.03)
sHemoglobin (g/dl) 0.90 (0.82–0.99)* 0.90 (0.75–1.07) 0.93(0.77–1.14)
sFerritin 1.00 (0.99–1.0007) 1.00 (0.99–1.001) 1.00 (0.99–1.00)
EPO (per 1000units) 0.99 (0.95–1.04) 0.99 (0.92–1.07) 0.96 (0.89–1.03)
* p < 0.05
sAlbumin—serum albumin; sCholesterol—serum cholesterol—CXP—Calcium-phosphate product.; sHaemoglobin—serum haemoglobin; sFerritin—serum
ferritin; EPO—Erythropoietin
doi:10.1371/journal.pone.0156642.t003
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dialysis commencement, comorbidity (diabetes mellitus), anaemia (using haemoglobin as a
measure), and baseline serum albumin(Table 4). Likewise, baseline haemoglobin remained a
predictor of all-cause mortality with a 13% reduction in risk of death from all-causes for every
unit increase in haemoglobin levels (HR: 0.87 CI: 0.79–0.97, p = 0.01). Mortality risk according
dialysis modality was significantly modified by diabetes mellitus status on both univariate and
multivariable analyses (Table 5). Mortality risk was approximately 5 times higher among dia-
betics who had CAPD relative to non-diabetics on HD (HR: 4.99, CI: 2.13–11.71).
Discussion
In our study, we have demonstrated that CAPD as an RRT option among predominantly
rural-dwelling ESRD patients is associated with increased all-cause and infection-related risks
of death. An increased risk of death from all-causes has been described in mortality outcome
studies among dialysis patients in developed and developing countries. Among CAPD patients
in Mexico, 1 and 3- year survival was poor at 67% and 48% respectively while Stack et al
reported increasing adjusted relative risks for death among PD patients as duration of dialysis
increased with the maximum risk demonstrable 24 months after dialysis initiation (HR 1.37,
CI:1.25–1.51, p<0.001).[13, 14] However, we could not demonstrate an interaction between
modality and duration on dialysis but we noticed that CAPD patients who died had a signifi-
cantly short duration of follow-up than CAPD patients who remained alive (20.2 ± 16.3 vs
31.9 ± 22.6 months, p<0.001). The risk for all-cause mortality among CAPD patients increased
after adjustment for DM, systemic hypertension, and select baseline parameters (HR 1.98, CI:
1.28–3.05, p = 0.002). The modifying effect of DM (as a cause of ESRD and comorbidity) on
Table 4. Multivariate Cox regression model of the baseline predictors of all-causemortality.
Characteristic Hazard ratio Conﬁdence intervals p-value
Modality (PD) 2.00 1.29–3.10 0.002
Diabetes mellitus (present) 1.67 0.92–3.02 0.09
Hypertension (present) 0.86 0.52–1.41 0.55
sHemoglobin (g/dl) 0.87 0.79–0.97 0.01
sAlbumin (g/L) 0.98 0.97–1.00 0.25
Weight (kg) 0.98 0.97–1.00 0.07
sAlbumin—serum albumin; sHaemoglobin—serum haemoglobin; sFerritin
doi:10.1371/journal.pone.0156642.t004
Table 5. Univariate andMultivariate relative risks of all-causemortality according to Diabetes status
and dialysis modality.
Unadjusted model Adjusted Model #
Hazard ratio CI Hazard ratio CI
DM- HD Ref Ref Ref Ref
DM + HD 1.03 0.44–2.42 1.02 0.43–2.50
DM- PD 1.47 0.94–2.31 1.63 1.01–2.621
DM+ PD 3.44 1.54–7.67* 4.99 2.13–11.71*
# adjusted for age, albumin, cholesterol and hemoglobin at baseline
Ref- reference group
* P < 0.001;
1 p< 0.05
doi:10.1371/journal.pone.0156642.t005
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mortality in PD patients is well known.[15] Vonesh et al reported an age and co-morbidity
adjusted average mortality risk ratio of 1.22 among United States (US) Medicare incident dialy-
sis patients with DM.[16] There was a significant increase in the risk of death among our DM
patients on PD (adjusted HR: 4.99, CI: 2.13–11.71, p<0.001) [Table 5]. Differences in patient
characteristics at baseline may explain our higher mortality rates. Patients in PKDC were at
baseline more malnourished than the US Medicare group with lower mean serum albumin lev-
els. Nineteen percent of patients (19.0%) within the US cohort on PD had serum albumin level
<31g/L in comparison to 56.9% of our patients. Serum albumin is a recognised marker of mal-
nutrition in dialysis patients, and in turn, malnutrition a known predictor of poor outcome in
PD. Baseline haemoglobin levels were also lower among our patients at dialysis initiation.
Over the decades, infection-related deaths have accounted for the majority of non-CV
deaths among dialysis patients.[17, 18] The risk of death from infection-related causes was sig-
nificantly higher among our PD patients with peritonitis being the commonest cause of infec-
tion. The relationship between peritonitis and outcomes in PD is well-established. An analysis
of the Australian-New Zealand data base demonstrated the notable role peritonitis played in
the mortality of PD patients.[19] Infection rates vary among peritoneal dialysis modalities with
the lowest risk associated with automated peritoneal dialysis (APD) systems.[20] In our cohort,
CAPD was the PD modality utilized and may have accounted for the observed peritonitis and
death occurrences. Peritonitis rates in PD programs are usually a reflection of the standard of
care in PD programs. Factors that can be attributed to the possibility of sub-optimal standard
of care among our patients are technical manpower shortages and lack of adequate infrastruc-
ture in health services systems in rural settings. In rural, underdeveloped regions of china
where there are significantly less doctors and trained health staff in PD programs, PD outcomes
have been noted to be poor in comparison to PD patients with access to adequately staffed
urban units.[21, 22] The relative lack of nearby standard PD services in our patients’ locale is
brought to bear in the average distance travelled to access care (114.3 ± 70.2 km). Cost consid-
erations in making these journeys will most certainly deter early presentation for prompt inter-
vention when peritonitis symptoms develop. Our patients are largely unemployed and those
accepted unto the chronic dialysis program are given 1200 Rands (approximately $85) per
month in form of a social grant by the provincial government. The lack of an association
between infection-related mortality and type of housing mirrors the positive impact of good
housing conditions in infection control. A significantly higher proportion of PD patients dwelt
in formal houses which are characterized in South Africa by the presence of running water and
proper sewage disposal systems. In an attempt not to make invalid associations, we did not fur-
ther assess the relationship among risk of infection-related death, peritonitis and type of hous-
ing because of the small numbers.
Cardiovascular causes account for the majority of deaths among chronic dialysis patients.
[23] In our cohort of patients however, deaths related to CV causes accounted for only 29.3%
of all deaths with body weight at dialysis initiation being the only significantly associated factor
for CV mortality. We recognise that this low proportion of CV deaths can be accounted for by
selection bias whereby patients who are healthier, younger, and with less comorbidities and CV
disease burden are dialysed. This is apparent in the mean age of our patients (36.1 ± 11.9
years), mean BMI (23.9 ± 5.5 Kg/m2) and the percentage of patients with DM (10.3%) and
hypertension (25.9%) in a predominantly black population of patients. Due to the current dial-
ysis-rationing policy operational in government-funded dialysis centres in South Africa (ours
inclusive), stringent criteria are applied in accepting ESRD patients to the maintenance dialysis
program.[24] The exclusion criteria under this policy are factors that are known to be associ-
ated with poor CV outcomes. As such patients who are> 60 years, diabetic (if> 50 years),
Baseline Predictors of Mortality in Chronic Dialysis Patients in Limpopo, South Africa
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morbidly obese (>BMI.35kg/m2) and those with advanced and irreversibly progressive car-
diac, CV or peripheral vascular disease are not accepted on to the program.
Peritoneal dialysis has the potential of being a preferred RRT option in developing countries
as it could serve rural dwelling patients who commonly live far away from in-centre HD units
which are usually cited in urban areas. However, poorer patient outcomes in PD patients may
prevent its optimal usage among this group of patients in a country like South Africa. Even
though this study has described poorer survival among PD patients, this should not discourage
the use of PD as an RRT modality given that it can be relatively cheaper than HD, requiring
minimal supervision by trained nephrologists and creating time for the patient to be otherwise
gainfully employed.[25] The opportunity to be able to keep a job is especially important in a
young ESRD population like ours. Moreover, we have previously reported comparable out-
comes for patients on PD in South Africa with those from developed countries.[26]
Our study is not without a number of limitations. Its retrospective design (with the inherent
problem of missing records) made it difficult to assess all relevant socioeconomic, clinical and
laboratory parameters known to be associated with mortality in dialysis patients as these had
not been adequately documented. From the foregoing also, the efficiency of the delivered dose
of therapy (HD and PD) over the duration could not be reliably extracted. However given the
socioeconomic and demographic landscape of South Africa, this type of study can be prospec-
tively set up to investigate mortality outcomes among rural dwellers. Similarly, comparative
prospective studies assessing the outcomes between rural and urban dwellers will further define
the clinical epidemiology of dialysis therapies in South Africa.
In conclusion, we have established that in rural dwelling ESRD patients receiving dialysis
therapies in South Africa, CAPD is associated an increased risk of all-cause and infection-
related mortality. We believe that poor access to health care facilities plays a contributory role
in infection-related mortality and we thus advocate for the establishment of CAPD centres in
rural areas of South Africa.
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